Results 51 to 60 of about 45,806 (246)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab

Journal of Thrombosis and Haemostasis, 2020
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody ...
L. Völker, P. Brinkkoetter, P. Knöbl, M. Krstić, J. Kaufeld, J. Menne, V. Buxhofer-Ausch, W. Miesbach   +7 more
semanticscholar   +1 more source

Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome [PDF]

, 2010
Thrombotic microangiopathies (TMAs) are pathological conditions characterized by generalized microvascular occlusion by platelet thrombi, thrombocytopenia, and microangiopathic hemolytic anemia.
Mastroianni Kirsztajn, Gianna, Polito, Maria Goretti   +1 more
core   +2 more sources

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

New England Journal of Medicine, 2016
BACKGROUND Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on ultralarge von Willebrand factor multimers. This microvascular thrombosis causes multiorgan ischemia with potentially life-threatening complications ...
F. Peyvandi, M. Scully, J. K. Kremer Hovinga, S. Cataland, P. Knöbl, Haifeng M. Wu, A. Artoni, J. Westwood, M. Mansouri Taleghani, B. Jilma, F. Callewaert, H. Ulrichts, C. Duby, D. Tersago   +13 more
semanticscholar   +1 more source

Graves disease-induced thrombotic thrombocytopenic purpura: a case report

Journal of Medical Case Reports, 2019
Background Thrombotic thrombocytopenic purpura is an autoimmune disease that carries a high mortality. Very few case reports in the literature have described a relationship between Graves disease and thrombotic thrombocytopenic purpura. We present a case
Saira Chaughtai, Ijaz Khan, Varsha Gupta, Zeeshan Chaughtai, Raquel Ong, Arif Asif, Mohammad A. Hossain   +6 more
doaj   +1 more source

Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain

Haematologica, 2011
Background The majority of patients diagnosed with thrombotic thrombocytopenic purpura have autoantibodies directed towards the spacer domain of ADAMTS13.Design and Methods In this study we explored the epitope specificity and immunoglobulin class and ...
Wouter Pos, Nicoletta Sorvillo, Rob Fijnheer, Hendrik B. Feys, Paul H.P Kaijen, Gestur Vidarsson, Jan Voorberg   +6 more
doaj   +1 more source

Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion [PDF]

, 2016
INTRODUCTION: Over 150 mutations have been identified in the ADAMTS13 gene in patients with congenital thrombotic thrombocytopenic purpura (TTP). The majority of these (86%), lead to reduced (
Garagiola, I, Machin, S, Mackie, I, Peyvandi, F, Underwood, M   +4 more
core   +1 more source

Characterization and treatment of congenital thrombotic thrombocytopenic purpura.

Blood, 2019
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombomicroangiopathy caused by an inherited deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13).
F. Alwan, C. Vendramin, R. Liesner, A. Clark, W. Lester, T. Dutt, W. Thomas, R. Gooding, T. Biss, Henry G. Watson, N. Cooper, R. Rayment, T. Cranfield, J. J. Veen, Q. Hill, Sarah Davis, J. Motwani, N. Bhatnagar, Nicole Priddee, M. Dávid, Maeve P. Crowley, J. Alamelu, H. Lyall, J. Westwood, M. Thomas, M. Thomas, M. Scully, M. Scully   +27 more
semanticscholar   +1 more source

Vitamin B12 deficiency-induced pseudothrombotic microangiopathy without macrocytosis presenting with acute renal failure: a case report

Journal of Medical Case Reports, 2018
Background Vitamin B12 deficiency-induced thrombotic microangiopathy, known as pseudothrombotic microangiopathy, is a rare condition which resembles the clinical features of thrombotic thrombocytopenic purpura but requires a markedly different treatment.
Jennifer Vanoli, Andrea Carrer, Roberto Martorana, Guido Grassi, Michele Bombelli   +4 more
doaj   +1 more source

Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report

Journal of Medical Case Reports, 2018
Background Thrombotic thrombocytopenic purpura is a very rare hereditary blood deficiency disorder of ADAMTS13 (von Willebrand factor-cleaving protease) and a life-threatening thrombotic microangiopathy characterized by thrombocytopenia and ...
Valter Romão de Souza, Ana Beatriz Cavalcante de Oliveira, Ana Maria Vanderlei, Amanda Queiroz da Mota Silveira Aroucha, Bruna Pontes Duarte, Aureli Nunes Machado, Lívia Netto Chaer, Cláudia Wanderley de Barros Correia, Maria da Conceição de Barros Correia, Manuela Freire Hazin Costa   +9 more
doaj   +1 more source

Coma in thrombotic thrombocytopenic purpura [PDF]

BMJ Case Reports, 2010
Thrombotic thrombocytopenic purpura (TTP) is characterised by a thrombotic, haemolytic microangiopathy leading to microvascular occlusion, haemolysis and ischaemic dysfunction of various organs including the brain. TTP may present with a variety of neurological symptoms, including headache, focal deficits, seizures and coma.
Bram Jacobs, F J de Jong, Diederik W.J. Dippel, P A W te Boekhorst   +3 more
openaire   +3 more sources